Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective

Mickael Hiligsmann; Setareh A. Williams; Lorraine A. Fitzpatrick; Stuart S. Silverman; Richard Weiss; Jean-Yves Reginster

doi:10.1016/j.semarthrit.2020.02.004

Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective

Mickael Hiligsmann^*, Setareh A. Williams, Lorraine A. Fitzpatrick, Stuart S. Silverman, Richard Weiss, Jean-Yves Reginster

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Web of Science)

Original language	English
Pages (from-to)	394-400
Number of pages	7
Journal	Seminars in Arthritis and Rheumatism
Volume	50
Issue number	3
DOIs	https://doi.org/10.1016/j.semarthrit.2020.02.004
Publication status	Published - Jun 2020

Keywords

Abaloparatide
Alendronate
Economic evaluation
Monotherapy
Osteoporosis
Sequential treatmen
QUALITY-OF-LIFE
POSTMENOPAUSAL WOMEN
ORAL BISPHOSPHONATES
VERTEBRAL FRACTURES
SEVERE OSTEOPOROSIS
ECONOMIC-EVALUATION
EXCESS MORTALITY
UNITED-STATES
HIP FRACTURE
HEALTH

Access to Document

10.1016/j.semarthrit.2020.02.004Licence: CC BY

Cite this

Hiligsmann, M., Williams, S. A., Fitzpatrick, L. A., Silverman, S. S., Weiss, R., & Reginster, J-Y. (2020). Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective. Seminars in Arthritis and Rheumatism, 50(3), 394-400. https://doi.org/10.1016/j.semarthrit.2020.02.004

Hiligsmann, Mickael ; Williams, Setareh A. ; Fitzpatrick, Lorraine A. ; Silverman, Stuart S. ; Weiss, Richard ; Reginster, Jean-Yves. / Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture : A US payer perspective. In: Seminars in Arthritis and Rheumatism. 2020 ; Vol. 50, No. 3. pp. 394-400.

@article{180a75ace8e74e84be48468f5a70ee45,

title = "Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective",

keywords = "Abaloparatide, Alendronate, Economic evaluation, Monotherapy, Osteoporosis, Sequential treatmen, QUALITY-OF-LIFE, POSTMENOPAUSAL WOMEN, ORAL BISPHOSPHONATES, VERTEBRAL FRACTURES, SEVERE OSTEOPOROSIS, ECONOMIC-EVALUATION, EXCESS MORTALITY, UNITED-STATES, HIP FRACTURE, HEALTH",

author = "Mickael Hiligsmann and Williams, {Setareh A.} and Fitzpatrick, {Lorraine A.} and Silverman, {Stuart S.} and Richard Weiss and Jean-Yves Reginster",

year = "2020",

month = jun,

doi = "10.1016/j.semarthrit.2020.02.004",

language = "English",

volume = "50",

pages = "394--400",

journal = "Seminars in Arthritis and Rheumatism",

issn = "0049-0172",

publisher = "W B Saunders Co-Elsevier Inc ",

number = "3",

}

Hiligsmann, M, Williams, SA, Fitzpatrick, LA, Silverman, SS, Weiss, R & Reginster, J-Y 2020, 'Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective', Seminars in Arthritis and Rheumatism, vol. 50, no. 3, pp. 394-400. https://doi.org/10.1016/j.semarthrit.2020.02.004

Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture : A US payer perspective. / Hiligsmann, Mickael; Williams, Setareh A.; Fitzpatrick, Lorraine A.; Silverman, Stuart S.; Weiss, Richard; Reginster, Jean-Yves.

In: Seminars in Arthritis and Rheumatism, Vol. 50, No. 3, 06.2020, p. 394-400.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture

T2 - A US payer perspective

AU - Hiligsmann, Mickael

AU - Williams, Setareh A.

AU - Fitzpatrick, Lorraine A.

AU - Silverman, Stuart S.

AU - Weiss, Richard

AU - Reginster, Jean-Yves

PY - 2020/6

Y1 - 2020/6

KW - Abaloparatide

KW - Alendronate

KW - Economic evaluation

KW - Monotherapy

KW - Osteoporosis

KW - Sequential treatmen

KW - QUALITY-OF-LIFE

KW - POSTMENOPAUSAL WOMEN

KW - ORAL BISPHOSPHONATES

KW - VERTEBRAL FRACTURES

KW - SEVERE OSTEOPOROSIS

KW - ECONOMIC-EVALUATION

KW - EXCESS MORTALITY

KW - UNITED-STATES

KW - HIP FRACTURE

KW - HEALTH

U2 - 10.1016/j.semarthrit.2020.02.004

DO - 10.1016/j.semarthrit.2020.02.004

M3 - Article

C2 - 32160943

VL - 50

SP - 394

EP - 400

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 3

ER -